HOSHINO Junichi    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Professor and Division head
Article types	Original article
Language	English
Peer review	Non peer reviewed
Title	Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022.
Journal	Formal name：International journal of clinical oncology Abbreviation：Int J Clin Oncol ISSN code：14377772/13419625
Volume, Issue, Page	28(10),pp.1333-1342
Author and coauthor	Ishikura Kenji, Omae Kenji, Sasaki Sho, Shibagaki Yugo, Ichioka Satoko, Okuda Yusuke, Koitabashi Kenichiro, Suyama Koichi, Mizukami Takuro, Kondoh Chihiro, Hirata Sumio, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko
Publication date	2023/10/28
Summary	Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible.
DOI	10.1007/s10147-023-02375-1
PMID	37418141